The rapid advancement of messenger RNA (mRNA) therapeutics and vaccines has revolutionized modern medicine. However, the manufacturing process, specifically in vitro transcription (IVT) using a linearized plasmid DNA template, introduces potential process-related impurities. At CD BioGlyco, we provide a comprehensive mRNA residual plasmid DNA analysis service designed to ensure the safety, purity, and regulatory compliance of your mRNA products. Leveraging our deep expertise in mRNA structural characterization, we offer ultra-sensitive detection and quantification solutions that meet the highest industry standards.
As a critical component of mRNA structural characterization within mRNA-based vaccine development, our service covers the entire spectrum of residual DNA analysis. We focus on identifying and quantifying DNA fragments that may remain after the enzymatic digestion of the template. Our analysis includes, but is not limited to:
We begin by analyzing your specific mRNA construct and plasmid map to identify the most effective target sequences for primer and probe design.
To minimize interference from the mRNA matrix or lipid nanoparticles (LNPs), we perform rigorous sample preparation, including enzymatic digestion and magnetic bead-based DNA extraction.
Every assay undergoes strict validation for specificity, linearity, precision, and the limit of quantification (LOQ) to ensure reliable results across different batches.
Utilizing either qPCR or ddPCR, we perform the amplification of target sequences under highly controlled conditions to detect femtogram-level DNA quantities.
Our bioinformaticians process the raw data, calculating the exact amount of residual DNA relative to the total RNA concentration or per dose.
Clients receive a detailed report including methodology, validation data, quantification results, and a comparison against regulatory thresholds.
DoI: 10.3390/mps3020040
Journal: Methods and Protocols
IF: 2.0
Published: 2020
Results: This study addresses the challenge of distinguishing plasmid-derived mRNA from endogenous genome-derived mRNA and residual plasmid DNA in reverse transcriptase quantitative PCR (RT-qPCR) after mammalian cell transfection. When transfecting MC3T3-E1 cells with a Pex11β cDNA plasmid, standard RT-qPCR yielded unrealistically high signals due to plasmid DNA contamination, which DNase I treatment failed to eliminate completely. The researchers developed a modified two-step RT-qPCR method: a nonsense-tail RT primer selectively reverse-transcribes plasmid-derived mRNA, and subsequent qPCR uses primers targeting the plasmid cDNA and nonsense tail. This method specifically quantifies plasmid-derived mRNA with minimal detection of endogenous mRNA. It also reveals that high plasmid DNA levels disrupt RNA isolation purity. The protocol provides a simple, specific tool to assess transfection and transcription efficiency.
Fig.1 Schematic drawing of the mouse Pex11β gene and the Pex11β cDNA inserted into the expression vector. (Ahlemeyer, et al., 2020)
mRNA Vaccine R&D
Essential for characterizing the purity of vaccine candidates during early discovery and preclinical stages, ensuring that only the highest quality transcripts move forward in the pipeline.
Cancer Immunotherapy
Critical for monitoring process-related impurities in personalized neoantigen vaccines, where the safety profile must be meticulously documented for regulatory approval.
Gene Therapy Developmemt
Used to validate the removal of DNA templates in mRNA-based protein replacement therapies, supporting long-term safety assessments for chronic administration in vulnerable patient populations.
Manufacturing Process Optimization
Enables developers to evaluate the efficiency of DNase treatment and purification steps, allowing for the fine-tuning of downstream processes to minimize residual contamination.
Ultra-High Sensitivity
By utilizing ddPCR technology, we achieve absolute quantification with a sensitivity that reaches the femtogram level, far exceeding traditional fluorometric methods for complex mRNA samples.
Customized Assay Development
We do not rely on "one-size-fits-all" kits; our team designs custom primers and probes specifically for your plasmid's unique sequence to ensure maximum specificity.
Robust Matrix Tolerance
Our optimized extraction protocols effectively remove inhibitors from LNPs and high concentrations of mRNA, ensuring accurate quantification even in final formulated drug products.
Expert Technical Support
Clients have direct access to our specialist team for data interpretation and consulting on regulatory strategy regarding process-related impurities in mRNA therapeutics.
"The sensitivity of the ddPCR assay provided by CD BioGlyco was instrumental. Their ability to quantify residual DNA in our LNP-formulated product with such precision gave us great confidence in our safety data."
– C.T., Biopharmaceutical Company
"We were struggling with matrix interference using standard kits. The custom extraction and assay design from the CD BioGlyco team solved our issue."
– S.T., Biotech Startup
"Professional, scientifically sound, and timely. Their expertise in mRNA impurities is evident in the quality of their technical reports and the responsiveness of their support team."
– H.T., mRNA Vaccine Manufacturer
CD BioGlyco combines cutting-edge technology with deep biological expertise to provide the most reliable residual DNA analysis services in the industry. Whether you are in early-stage R&D or moving toward commercial manufacturing, we are your dedicated partner in quality and safety. Please feel free to contact us for more information and to discuss your project.
Reference
